title: Prothymosin alpha1 effects on IL-2-induced expression of LFA-1 on lymphocytes and their adhesion to human umbilical vein endothelial cells.
abstract: Prothymosin alpha1 (Pro alpha1) is known to stimulate in vitro and in vivo natural killer (NK) and lymphokine (IL-2)-activated killer (LAK) cells against tumor cells. In this process, LAK cells first adhere to endothelial cells in vivo, raising the question whether Pro alpha1 affects this interaction as well. The binding ability of peripheral blood lymphocytes (PBL) to human umbilical vein endothelial cells (HUVEC) was increased by incubation with IL-2 in a concentration-dependent manner, reaching a maximal value at 20U/ml IL-2. Although Pro alpha1 alone was without any stimulating effect, it significantly increased PBL binding to unstimulated HUVECs in combination with suboptimal IL-2 (5 and 10 U/ml). The combination of Pro alpha1 (1 microg/ml) and 5 U/ml or 10 U/ml IL-2 is as effective as 10 U/ml or 20 U/ml IL-2 alone. This Pro alpha1 effect on IL-2-activated lymphocytes was found to be augmented on IL-1 or tumor necrosis factor (TNF)-alpha-activated endothelial cells. Analyzing the effect of Pro alpha1 on IL-2-activated lymphocytes by flow cytometry revealed an increase of CD16, CD56, and CD18 surface marker expression, whereas CD3, CD11a/b, CD49d, and CD54 were not affected. In conclusion, Pro alpha1 functions as a mediator of the adhesion of IL-2-activated lymphocytes to HUVECs.
authors.affiliation: Institute of Pharmacy, Free University of Berlin, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Grünberg
authors.forename: K
authors.initials: K
authors.lastname: Eckert
authors.forename: H R
authors.initials: HR
authors.lastname: Maurer
authors.forename: P
authors.initials: P
authors.lastname: Immenschuh
authors.forename: E D
authors.initials: ED
authors.lastname: Kreuser
mesh_terms: D015703:Antigens, CD / Q000097:blood; D000954:Antigens, Surface / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002448:Cell Adhesion / Q000187:drug effects; D002478:Cells, Cultured; D004357:Drug Synergism; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000096:biosynthesis*; D008214:Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D011498:Protein Precursors / Q000494:pharmacology*; D013947:Thymosin / Q000031:analogs & derivatives* / Q000494:pharmacology; D014471:Umbilical Veins / Q000187:drug effects
chemical_list: D015703:Antigens, CD; D000954:Antigens, Surface; D015415:Biomarkers; D007376:Interleukin-2; D016169:Lymphocyte Function-Associated Antigen-1; D011498:Protein Precursors; C040782:prothymosin alpha; D013947:Thymosin